Kang Xue-Ling, Zou Hong, Pang Li Juan, Hu Wen Hao, Zhao Jin, Qi Yan, Liu Chun-Xia, Hu Jian Ming, Tang Jing-Xia, Li Hong An, Liang Wei Hua, Yuan Xiang-Lin, Li Feng
Department of Pathology, Shihezi University School of Medicine, Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Ministry of Education of China Shihezi, Xinjiang, China ; Department of Pathology and Pathophysiology, Fudan University School of Medicine Shanghai, China.
Department of Pathology, Shihezi University School of Medicine, Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Ministry of Education of China Shihezi, Xinjiang, China ; Tongji Hospital Cancer Center, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China.
Int J Clin Exp Pathol. 2015 Apr 1;8(4):3636-47. eCollection 2015.
Renal cell carcinoma (RCC) accounts for approximately 3% of all new cancer cases. Although the classification of RCC is based mainly on histology, this method is not always accurate. We applied comparative genomic hybridization (CGH) to determine genomic alterations in 46 cases of different RCC histological subtypes [10 cases of clear cell RCC (CCRCC), 13 cases of papillary RCC (PRCC), 12 cases of chromophobe RCC (CRCC), 9 cases of Xp11.2 translocation RCC (Xp11.2RCC), 2 cases of undifferentiated RCC (unRCC)], and investigated the relationships between clinical parameters and genomic aberrations. Changes involving one or more regions of the genome were seen in all RCC patients; DNA sequence gains were most frequently (>30%) seen in chromosomes 7q, 16p, and 20q; losses from 1p, 3p, 13q, 14q, and 8p. We conclude CGH is a useful complementary method for differential diagnosis of RCC. Loss of 3p21-25, 15q, and gain of 16p11-13 are relatively particular to CCRCC vs. other types of RCC. Gain of 7p13-22, 8q21-24, and loss of 18q12-ter, 14q13-24, and Xp11-q13/Y are more apparent in PRCC, and gain of 8q21-24 is characteristic of type 2 PRCC vs. type 1 PRCC. Loss of 2q12-32, 10p12-15, and 11p11-15, 13p are characteristic of CRCC, and gain of 3p and loss of 11p11-15 and 13p are significant differentiators between common CRCC and CRCC accompanied by sarcomatous change groups. Gain of Xp11-12 is characteristic of the Xp11.2RCC group. Based on Multivariate Cox regression analysis, aberration in 5 chromosome regions were poor prognostic markers of RCC, and include the gain of chromosome 12p12-ter (P = 0.034, RR = 3.502, 95% CI 1.097-11.182), 12q14-ter (P = 0.002, RR = 5.115, 95% CI 1.847-14.170), 16q21-24 (P = 0.044, RR = 2.629, 95% CI 1.027-6.731), 17p12-ter (P = 0.017, RR = 3.643, 95% CI 1.262-10.512) and the loss of 18q12-23 (P = 0.049, RR = 2.911, 95% CI 1.006-8.425), which may provide clues of new genes involved in RCC tumorigenesis.
肾细胞癌(RCC)约占所有新发癌症病例的3%。虽然RCC的分类主要基于组织学,但这种方法并不总是准确的。我们应用比较基因组杂交(CGH)来确定46例不同RCC组织学亚型(10例透明细胞RCC(CCRCC)、13例乳头状RCC(PRCC)、12例嫌色细胞RCC(CRCC)、9例Xp11.2易位性RCC(Xp11.2RCC)、2例未分化RCC(unRCC))中的基因组改变,并研究临床参数与基因组畸变之间的关系。所有RCC患者均可见涉及基因组一个或多个区域的变化;DNA序列增益最常见于(>30%)7q、16p和20q染色体;1p、3p、13q、14q和8p染色体存在缺失。我们得出结论,CGH是RCC鉴别诊断的一种有用的补充方法。与其他类型的RCC相比,3p21 - 25、15q缺失以及16p11 - 13增益相对是CCRCC所特有的。7p13 - 22、8q21 - 24增益以及18q12 - ter、14q13 - 24缺失和Xp11 - q13/Y在PRCC中更为明显,8q21 - 24增益是2型PRCC相对于1型PRCC的特征。2q12 - 32、10p12 - 15和11p11 - 15、13p缺失是CRCC的特征,3p增益以及11p11 - 15和13p缺失是普通CRCC与伴有肉瘤样改变的CRCC组之间的重要鉴别指标。Xp11 - 12增益是Xp11.2RCC组的特征。基于多变量Cox回归分析,5个染色体区域的畸变是RCC的不良预后标志物,包括12p12 - ter染色体增益(P = 0.034,RR = 3.502,95%CI 1.097 - 11.182)、12q14 - ter染色体增益(P = 0.002,RR = 5.115,95%CI 1.847 - 14.170)、16q21 - 24染色体增益(P = 0.044,RR = 2.629,95%CI 1.027 - 6.731)、17p12 - ter染色体增益(P = 0.017,RR = 3.643,95%CI 1.262 - 10.512)以及18q12 - 23染色体缺失(P = 0.049,RR = 2.911,95%CI 1.006 - 8.425),这可能为参与RCC肿瘤发生的新基因提供线索。